Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

Authors: Paul A Kristiansen, Absatou Ky Ba, Abdoul-Salam Ouédraogo, Idrissa Sanou, Rasmata Ouédraogo, Lassana Sangaré, Fabien Diomandé, Denis Kandolo, Inger Marie Saga, Lara Misegades, Thomas A Clark, Marie-Pierre Préziosi, Dominique A Caugant

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is currently being introduced throughout the African meningitis belt. In repeated multicentre cross-sectional studies in Burkina Faso we demonstrated a significant effect of vaccination on NmA carriage for one year following mass vaccination in 2010. A new multicentre carriage study was performed in October-November 2012, two years after MenAfriVac mass vaccination.

Methods

Oropharyngeal samples were collected and analysed for presence of N. meningitidis (Nm) from a representative selection of 1-29-year-olds in three districts in Burkina Faso using the same procedures as in previous years. Characterization of Nm isolates included serogrouping, multilocus sequence typing, and porA and fetA sequencing. A small sample of invasive isolates collected during the epidemic season of 2012 through the national surveillance system were also analysed.

Results

From a total of 4964 oropharyngeal samples, overall meningococcal carriage prevalence was 7.86%. NmA prevalence was 0.02% (1 carrier), significantly lower (OR, 0.05, P = 0.005, 95% CI, 0.006-0.403) than pre-vaccination prevalence (0.39%). The single NmA isolate was sequence type (ST)-7, P1.20,9;F3-1, a clone last identified in Burkina Faso in 2003. Nm serogroup W (NmW) dominated with a carriage prevalence of 6.85%, representing 87.2% of the isolates. Of 161 NmW isolates characterized by molecular techniques, 94% belonged to the ST-11 clonal complex and 6% to the ST-175 complex. Nm serogroup X (NmX) was carried by 0.60% of the participants and ST-181 accounted for 97% of the NmX isolates. Carriage prevalence of serogroup Y and non-groupable Nm was 0.20% and 0.18%, respectively. Among the 20 isolates recovered from meningitis cases, NmW dominated (70%), followed by NmX (25%). ST-2859, the only ST with a serogroup A capsule found in Burkina Faso since 2004, was not found with another capsule, neither among carriage nor invasive isolates.

Conclusions

The significant reduction of NmA carriage still persisted two years following MenAfriVac vaccination, and no cases of NmA meningitis were recorded. High carriage prevalence of NmW ST-11 was consistent with the many cases of NmW meningitis in the epidemic season of 2012 and the high proportion of NmW ST-11 among the characterized invasive isolates.
Appendix
Available only for authorised users
Literature
1.
Greenwood B: Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999, 93: 341-353. 10.1016/S0035-9203(99)90106-2.CrossRefPubMed
2.
Teyssou R, Muros-Le RE: Meningitis epidemics in Africa: a brief overview. Vaccine. 2007, 25 (Suppl. 1): A3-A7. 10.1016/j.vaccine.2007.04.032.CrossRefPubMed
3.
Lapeyssonnie L: La méningite cérébrospinale en Afrique [in French]. Bull World Health Organ. 1963, 28 (Suppl): 3-114.
4.
Harrison LH, Trotter CL, Ramsay ME: Global epidemiology of meningococcal disease. Vaccine. 2009, 27 (Suppl. 2): B51-B63. 10.1016/j.vaccine.2009.04.063.CrossRefPubMed
5.
Stephens DS: Conquering the meningococcus. FEMS Microbiol Rev. 2007, 31: 3-14. 10.1111/j.1574-6976.2006.00051.x.CrossRefPubMed
6.
Yazdankhah SP, Caugant DA: Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004, 53: 9-32. 10.1099/jmm.0.45529-0.CrossRef
7.
Boisier P, Maïnassara HB, Sidikou F, Djibo S, Kairo KK, Chanteau S: Case-fatality ratio of bacterial meningitis in the African meningitis belt: We can do better. Vaccine. 2007, 25 (Suppl. 1): A24-A29. 10.1016/j.vaccine.2007.04.036.CrossRefPubMed
8.
Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA: Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol. 2005, 43: 5129-5135. 10.1128/JCM.43.10.5129-5135.2005.CrossRefPubMedPubMedCentral
9.
Koumaré B, Ouédraogo-Traoré R, Sanou I, Yada AA, Sow I, Lusamba PS, Traoré E, Dabal M, Santamaria M, Hacen MM, Kaboré AB, Caugant DA: The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine. 2007, 25 (Suppl. 1): A37-A41. 10.1016/j.vaccine.2007.04.038.CrossRefPubMed
10.
11.
Wuorimaa T, Kayhty H, Eskola J, Bloigu A, Leroy O, Surcel HM: Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand J Immunol. 2001, 53: 422-428. 10.1046/j.1365-3083.2001.00882.x.CrossRefPubMed
12.
Maiden MCJ, Stuart JM: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002, 359: 1829-1830. 10.1016/S0140-6736(02)08679-8.CrossRefPubMed
13.
Forleo-Neto E, De Oliveira CF, Maluf EMCP, Bataglin C, Araujo JMR, Kunz J, Pustai AK, Vieira VSD, Zanella RC, Brandileone MC, Mimica LM, Mimica IM: Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids- pertussis vaccine. J Infect Dis. 1999, 180: 1153-1158. 10.1086/315018.CrossRefPubMed
14.
Maiden MCJ, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, Ala’aladeen DA, Crook DW, Cann K, Harrison S, Cinningham R, Baxter D, Kaczmarski E, Maclennan J, Cameron JC, Stuart JM: Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008, 197: 737-743. 10.1086/527401.CrossRefPubMed
15.
Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E: Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br Med J. 2003, 326: 365-366. 10.1136/bmj.326.7385.365.CrossRef
16.
Vestrheim DF, Hoiby EA, Aaberge IS, Caugant DA: Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol. 2010, 17: 325-334. 10.1128/CVI.00435-09.CrossRefPubMedPubMedCentral
17.
LaForce FM, Konde K, Viviani S, Préziosi MP: The Meningitis Vaccine Project. Vaccine. 2007, 25 (Suppl): A97-A100. 10.1016/j.vaccine.2007.04.049.CrossRefPubMed
18.
LaForce FM, Okwo-Bele J-M: Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood). 2011, 30: 1049-1057. 10.1377/hlthaff.2011.0328.CrossRef
19.
Frasch CE, Préziosi MP, LaForce FM: Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother. 2012, 8: 715-724. 10.4161/hv.19619.CrossRefPubMed
20.
Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP: Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011, 364: 2293-2304. 10.1056/NEJMoa1003812.CrossRefPubMed
21.
Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Préziosi MP, Zuber PLF, Perea W, Hugonnet S, de RTN D, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, LaForce FM: Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012, 30 (Suppl): B40-B45. 10.1016/j.vaccine.2011.12.073.CrossRefPubMed
22.
Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, LaForce FM, Avokey F, Djingarey MH, Messonier NE, Tiendrébéogo S, Clark TA: Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012, 12: 757-764. 10.1016/S1473-3099(12)70168-8.CrossRefPubMedPubMedCentral
23.
Kristiansen PA, Diomandé F, Absatou KB, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA: Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013, 56: 354-363. 10.1093/cid/cis892.CrossRefPubMed
24.
Kristiansen PA, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Thomas JD, Clark TA, LaForce M, Caugant DA: Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infect Dis. 2013, 13: 363-10.1186/1471-2334-13-363.CrossRefPubMedPubMedCentral
25.
Daugla D, Gami J, Gamougam K, Naibei N, Mbainadji L, Narbé M, Toralta J, Kodbesse B, Ngadoua C, Coldiron M, Fermon F, Page AL, Djingarey MH, Hugonnet S, Harrison OB, Rebbetts LS, Tekletsion Y, Watkins ER, Hill D, Caugant DA, Chandramohan D, Hassan-King M, Manigart O, Nascimento M, Woukeu A, Trotter C, Stuart JM, Maiden MC, Greenwood BM: Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet. 2013, 383: 40-47. 10.1016/S0140-6736(13)61612-8.CrossRefPubMedPubMedCentral
26.
Kristiansen PA, Diomandé F, Wei SC, Ouédraogo R, Sangaré L, Sanou I, Kandolo D, Kaboré P, Clark TA, Ouédraogo AS, Absatou KB, Ouédraogo CD, Hassan-King M, Thomas JD, Hatcher C, Djingarey M, Messonnier N, Préziosi MP, LaForce M, Caugant DA: Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol. 2011, 18: 435-443. 10.1128/CVI.00479-10.CrossRefPubMedPubMedCentral
27.
Kristiansen PA, Ouédraogo AS, Sanou I, Absatou KB, Ouédraogo CD, Sangaré L, Ouédraogo R, Kandolo D, Diomandé F, Kaboré P, Hassan-King M, Thomas JD, Hatcher CP, Andreasson I, Clark TA, Préziosi MP, LaForce M, Caugant DA: Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso. Trans R Soc Trop Med Hyg. 2012, 106: 289-297. 10.1016/j.trstmh.2011.12.009.CrossRefPubMed
28.
29.
Ajello GW, Feeley JC, Hayes PS: Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae . J Clin Microbiol. 1984, 20: 1984-
30.
Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA, Feavers IM, Achtman M, Spratt BG: Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998, 95: 3140-3145. 10.1073/pnas.95.6.3140.CrossRefPubMedPubMedCentral
31.
Russell JE, Jolley KA, Feavers IM, Maiden MCJ, Suker J: PorA variable regions of Neisseria meningitidis . Emerg Infect Dis. 2004, 10: 674-678. 10.3201/eid1004.030247.CrossRefPubMedPubMedCentral
32.
Thompson EAL, Feavers IM, Maiden MCJ: Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology. 2003, 149: 1849-1858. 10.1099/mic.0.26131-0.CrossRefPubMed
33.
Taha M-K: Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis . J Clin Microbiol. 2000, 38: 855-857.PubMedPubMedCentral
34.
Caugant DA, Hoiby EA, Froholm LO, Brandtzaeg P: Polymerase chain reaction for case ascertainment of meningococcal meningitis: Application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis. 1996, 28: 149-153. 10.3109/00365549609049066.CrossRefPubMed
35.
Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, Ouédraogo R, Kandolo D, Bougoudogo F, Sow S, Bonte L: Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One. 2012, 7: e46019-10.1371/journal.pone.0046019.CrossRefPubMedPubMedCentral
36.
37.
MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FVK, Yelbeogo D, Kambou JL, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Hatcher C, Vuong J, Mayer LW, Djingarey MH, Clark TA, Messonnier NE: Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis. 2014, 20: 394-399. 10.3201/eid2003.131407.CrossRefPubMedPubMedCentral
38.
Kristiansen PA, Diomandé F, Ouédraogo R, Sanou I, Sangaré L, Ouédraogo AS, Ba AK, Kandolo D, Dolan Thomas J, Clark TA, Préziosi MP, LaForce FM, Caugant DA: Carriage of Neisseria lactamica in 1- to 29-year-old people in Burkina Faso: epidemiology and molecular characterization. J Clin Microbiol. 2012, 50: 4020-4027. 10.1128/JCM.01717-12.CrossRefPubMedPubMedCentral
39.
Medah I, Yélbeogo D, Kambou JL, Wannemuehler K, Goodson JL, Flannery B, Cohn A, Novak RT, Clark T, Messonnier NE, Meyer SA: Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign - Burkina Faso, 2011. Morb Mortal Wkly Rep. 2012, 61: 1022-1024.
40.
Beddek AJ, Li MS, Kroll JS, Jordan TW, Martin DR: Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun. 2009, 77: 2989-2994. 10.1128/IAI.00181-09.CrossRefPubMedPubMedCentral
41.
Simoes MJ, Cunha M, Almeida F, Furtado C, Brum L: Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002–2006. Epidemiol Infect. 2009, 137: 161-165. 10.1017/S0950268808001106.CrossRefPubMed
42.
Wang Q, Shao Z, Wang X, Gao Y, Li M, Xu L, Xu J, Wang L: Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serogroup A and C strains. Infect Immun. 2010, 78: 3883-3888. 10.1128/IAI.00363-10.CrossRefPubMedPubMedCentral
43.
Lancellotti M, Guiyoule A, Ruckly C, Hong E, Alonso JM, Taha MK: Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect. 2006, 8: 191-196. 10.1016/j.micinf.2005.06.012.CrossRefPubMed
44.
Traore Y, Njanpop-Lafourcade BM, Adjogble KL, Lourd M, Yaro S, Nacro B, Drabo A, du Parent Chatelet I, Mueller JE, Taha MK, Borrow R, Nicolas P, Alonso JM, Gessner BG: The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002–2005. Clin Infect Dis. 2006, 43: 817-822. 10.1086/507339.CrossRefPubMed
45.
Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, Firmenich P, Guerin PJ, Caugant DA: Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007, 13: 920-923. 10.3201/eid1306.060940.CrossRefPubMedPubMedCentral
46.
Fazio C, Neri A, Starnino S, Sofia T, Mastrantonio P, Stefanelli P: Characterization of invasive serogroup Y meningococci in Italy: prevalence of ST-23 Complex/Cluster A3. New Microbiol. 2008, 31: 467-472.PubMed
47.
Hedberg ST, Toros B, Fredlund H, Olcen P, Molling P: Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveillance 2011, 16.,
48.
Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, Ramsay ME, Kaczmarski EB, Borrow R: Invasive meningococcal capsular group Y disease, England and Wales, 2007–2009. Emerg Infect Dis. 2012, 18: 63-70. 10.3201/eid1801.110901.CrossRefPubMedPubMedCentral
49.
Leimkugel J, Hodgson A, Forgor AA, Pfluger V, Dangy JP, Smith T, Achtman M, Gagneux S, Pluschke G: Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight-year longitudinal study in northern Ghana. PLoS Med. 2007, 4: e101-10.1371/journal.pmed.0040101.CrossRefPubMedPubMedCentral
50.
Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomandé FV, Medah I, Jackson ML: Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt. PLoS One. 2013, 8: e63605-10.1371/journal.pone.0063605.CrossRefPubMedPubMedCentral
Metadata
Title
Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac
Authors
Paul A Kristiansen
Absatou Ky Ba
Abdoul-Salam Ouédraogo
Idrissa Sanou
Rasmata Ouédraogo
Lassana Sangaré
Fabien Diomandé
Denis Kandolo
Inger Marie Saga
Lara Misegades
Thomas A Clark
Marie-Pierre Préziosi
Dominique A Caugant
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-014-0663-4

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue

Research article

Lyme arthritis in Southern Norway - an endemic area for Lyme Borreliosis

Research article

Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniaebacteremia in Taiwan

Research article

Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older

Research article

Implications of screening and childcare exclusion policies for children with Shiga-toxin producing Escherichia coli infections: lessons learned from an outbreak in a daycare centre, Norway, 2012

Research article

Intra-abdominal aortic graft infection: prognostic factors associated with in-hospital mortality

Research article

CD4 T cell activation by B cells in human Leishmania (Viannia)infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits